Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.54 |
| ▸ | PTP4A2 | Q12974 | 1/20 | 0.54 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14911794 | 0.84 | GSK3B (0.56) | RAB9AALDH1A1HPGDLMNAMAPT | |
| SCHEMBL21963465 | 0.84 | RAB9A (0.40) | RAB9AALDH1A1HPGDLMNAPTP4A3 | |
| SCHEMBL13299937 | 0.76 | ESR1 (0.50) | RAB9AALDH1A1HPGDLMNAPTP4A3 | |
| SCHEMBL18137595 | 0.74 | ALDH1A1 (0.51) | RAB9AALDH1A1HPGDLMNAPTP4A3 | |
| SCHEMBL21963437 | 0.73 | ELANE (0.42) | RAB9AALDH1A1HPGDSMN1; SMN2MAPT | |
| SCHEMBL7835046 | 0.73 | PARP1 (0.39) | RAB9AALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL2367579 | 0.72 | ESR1 (0.47) | RAB9AALDH1A1HPGDLMNAPTP4A3 | |
| SCHEMBL12278801 | 0.72 | ESR1 (0.47) | RAB9AALDH1A1HPGDLMNAPTP4A3 | |
| SCHEMBL4341520 | 0.72 | ALDH1A1 (0.47) | RAB9AALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL1374464 | 0.72 | ALDH1A1 (0.69) | RAB9AALDH1A1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310355-B1 | PTP4A3 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV VIRGINIA PATENT FOUNDATION (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10308663-B2 | Inhibitors of PTP4A3 for the treatment of cancer | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180170946-A1 | INHIBITORS OF PTP4A3 FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-21 | — | — | US | disclosed |
| US-20180170946-A1 | INHIBITORS OF PTP4A3 FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-21 | — | — | US | disclosed |
| WO-2016205534-A1 | INHIBITORS OF PTP4A3 FOR THE TREATMENT OF CANCER | LAZO JOHN S (US) | 2016-12-22 | — | — | WO | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1556053-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556053-A1 | ANTIINFLAMMATION AGENTS | Amgen Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308663-B2 | Inhibitors of PTP4A3 for the treatment of cancer | PTP4A3, PTPRCAP, PTP4A1 | RAB9A 3017/4885ALDH1A1 1639/4885HPGD 2735/4885 |
| US-20180170946-A1 | INHIBITORS OF PTP4A3 FOR THE TREATMENT OF CANCER | PTP4A3, PTPRCAP, PTP4A1 | RAB9A 3017/4885ALDH1A1 1639/4885HPGD 2735/4885 |
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | RAB9A 3501/4885ALDH1A1 3037/4885HPGD 322/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | RAB9A 3501/4885ALDH1A1 3037/4885HPGD 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.